At a glance
The selected primary experiment is preclinical and short term. It provides a direct counterexample to treating a favourable weight marker as evidence of muscle preservation.
Identity & scope
LR 3 IGF-I is an IGF-I analogue. Findings on native IGF-I or another analogue should not be silently assigned to this material.
What the research shows
- The authors separately measured body weight, nitrogen balance and muscle-protein outcomes. Those measures did not all move in the same direction.
Critical interpretation
Body weight and muscle are not interchangeable outcomes
The food-restriction experiment measured several aspects of nutrient handling. Higher retained body weight and nitrogen did not prevent skeletal-muscle protein loss. This is why an anabolic headline needs the actual tissue and endpoint attached to it. The result applies to short-term restriction in rats; it neither proves a human benefit nor establishes that the compound can never have an anabolic effect in another model. [1]
Delivery and experimental stress change the comparison
The earlier study compared continuous delivery with injections in normally growing and dexamethasone-treated rats. LR3IGF-I’s relative potency varied by outcome, and stronger effects on some markers did not produce proportionately better reversal of carcass-muscle loss. Together, these studies show why binding-protein affinity or a body-weight response cannot serve as a shortcut to a human hypertrophy estimate. Species, nutritional state, induced catabolism and the method of exposure all remain part of the result. [2]
Limitations & uncertainties
- The experiment cannot establish human muscle growth, strength or a treatment benefit.
- Age and nutritional restriction affected the model’s response. It does not validate a supplied vial or nasal format.
Open research questions
- Does a study measure muscle protein and function, or only body weight?
- Is its molecule actually LR 3 IGF-I, and are its nutritional conditions relevant to the proposed experiment?
Selected papers & source records
Download bibliography1. Insulin-like growth factor-I (IGF-I) analogue, LR(3)IGF-I, ameliorates the loss of body weight but not of skeletal muscle during food restriction (opens in a new tab)
Tomas FM. (2001). Growth Hormone & IGF Research. DOI: 10.1054/ghir.2000.0194 (opens in a new tab) · PMID 11472075
- Design & population
- Seven-day food-restriction experiment in young and adult rats receiving LR 3 IGF-I or vehicle.
- What the study found
- Treated animals retained more body weight and nitrogen, but skeletal-muscle protein loss was not prevented. Adult rats showed adverse changes in muscle-protein turnover under restriction.
- Limits on interpretation
- Animal experiment under restricted nutrition. Body weight and nitrogen retention were not evidence of preserved muscle, and findings cannot establish a human strength benefit.
2. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection (opens in a new tab)
Tomas FM, Lemmey AB, Read LC, Ballard FJ. (1996). Journal of Endocrinology. DOI: 10.1677/joe.0.1500077 (opens in a new tab) · PMID 8708565
- Design & population
- Seven-day rat experiments comparing IGF-I with LR 3 IGF-I, continuous infusion with injection, and normal growth with dexamethasone-induced catabolism.
- What the study found
- Relative effects depended on delivery and endpoint. Greater effects on body weight or other markers did not mean proportionately greater reversal of carcass-muscle loss.
- Limits on interpretation
- Preclinical growth and catabolism models. Neither relative potency in rats nor delivery comparisons establish human muscle growth, strength or a validated nasal formulation.
Search & review scope
Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.
Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.
Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.
Recorded search terms
- site.pubmed.ncbi.nlm.nih.gov/11472075/ (direct record check)
- site.pubmed.ncbi.nlm.nih.gov "LR(3)IGF-I" "muscle" "rats"
- "8708565" DOI authors
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. IGF-1 LR3: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/igf-1-lr3.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.